MentionFox
Home › Stakes › AN2 Therapeutics, Inc.
5%+ stakes · Schedule 13D and 13G

AN2 Therapeutics, Inc.: 5%+ holders

Who has reported owning 5% or more of AN2 Therapeutics, Inc., from Schedule 13D and 13G filings: each holder's stake as filed, the timeline, and the purpose each 13D states, quoted.

At 5% or more4
Filings7
Latest filing2026-05-15

AN2 Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-11-14. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

HolderPercentSharesLatestEvent date
Commodore Capital LP9.9%3,697,435SCHEDULE 13G, 2026-03-162026-03-09
Vivo Opportunity Fund Holdings, L.P.8%2,864,346SCHEDULE 13G, 2026-03-132026-03-10
Eric Easom7.9%2,232,004SCHEDULE 13G/A, 2026-02-132025-12-31
Millennium Management LLC6.3%2,237,102SCHEDULE 13G, 2026-03-132026-03-06
Almitas Capital LLC4.1%1,479,129SCHEDULE 13G/A, 2026-05-152026-03-31

Timeline

FiledHolderPercentFiling
2025-11-14Almitas Capital LLC5.2%SCHEDULE 13G
2026-02-13Eric Easom7.9%SCHEDULE 13G/A
2026-02-17Almitas Capital LLC5.4%SCHEDULE 13G
2026-03-13Millennium Management LLC6.3%SCHEDULE 13G
2026-03-13Vivo Opportunity Fund Holdings, L.P.8%SCHEDULE 13G
2026-03-16Commodore Capital LP9.9%SCHEDULE 13G
2026-05-15Almitas Capital LLC4.1%SCHEDULE 13G/A

Tools for this story

Each opens in a new tab, filled in for AN2 Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/stakes/an2-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
AN2 Therapeutics, Inc. 5%+ holders: 4 at 5% or more, largest Commodore Capital LP 9.9%. MentionFox, 2026-09-27. https://mentionfox.com/stakes/an2-therapeutics